222 filings
Page 2 of 12
8-K
uewjq
28 Jun 23
Vistagen Provides Corporate Update and Reports Fiscal Year 2023 Financial Results
4:28pm
8-K
z56gr0eennhgbnm3
23 Jun 23
Other Events
8:35am
8-K
e6cc 9ri61l
21 Jun 23
Other Events
4:43pm
8-K
0evz0 r9dtj3ml4j3a
13 Jun 23
Vistagen Announces European Patent Office Intention to Grant New
5:30pm
8-K
jxi9gb8o 0w
7 Jun 23
Vistagen Announces Positive Results from Exploratory Phase 2A Study of PH80 in Women Diagnosed with Menopausal Hot Flashes
4:33pm
8-K
3zud392isnr5den7z
6 Jun 23
Vistagen Announces Stockholder-Approved Reverse Stock Split
9:26am
8-K
w1vj9 xbczars9gyu
1 Jun 23
Other Events
4:58pm
8-K
hgwh 789nyns
27 Apr 23
Regulation FD Disclosure
12:00am
8-K
n1no0q6oy uif
19 Apr 23
Vistagen Presents New Fasedienol (PH94B) Research at 2023 Anxiety and Depression Association of America Conference
4:49pm
8-K
zawbuca4xnevkmv7xi
6 Apr 23
Vistagen Receives New European Patent for AV-101
4:31pm
8-K
cbo7kpaywce8l017
30 Mar 23
Other Events
4:15pm
8-K
ipzer j96gp2hk1qu2j9
23 Mar 23
Vistagen Announces Positive Data in Fasedienol (PH94B) Phase 3
9:15am
8-K
1wdh8
8 Mar 23
Other Events
5:25pm
8-K
5mmga1kpg
7 Mar 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:40pm
8-K
qze rfr7wgf5d86o
1 Mar 23
Vistagen Announces Issuance of U.S. Patent for PH80 Nasal Spray for Treatment of Migraine
7:28pm
8-K
tpkja cbb14qipzrhjf
7 Feb 23
Vistagen Provides Corporate Update and Reports Fiscal 2023 Third Quarter Financial Results
4:29pm
8-K
kws 8zs90vr
2 Feb 23
Vistagen Announces Closing of Pherin Pharmaceuticals Acquisition
9:10am
8-K
tt4uue8ft
24 Jan 23
Vistagen Announces First Participants Dosed in Phase 1 Clinical Trial of PH10, an Investigational Pherine Nasal Spray for Major Depressive Disorder
5:32pm
8-K
rlsvbimz9z3zdp1er
11 Jan 23
Vistagen Announces Completion of Last Patient, Last Visit in Phase 2 Clinical Trial of PH94B for the Treatment of Adjustment Disorder with Anxiety
9:57pm
8-K
d4ei037pqp82ee
21 Dec 22
Vistagen to Acquire Pherin Pharmaceuticals
8:30am